Condition: Fatigue · Colon Cancer · Sponsor: Natureceuticals Sdn Bhd
The goal of this clinical trial is to evaluate whether Nuvastatic can reduce cancer-related fatigue in adult patients with colon cancer undergoing first-line chemotherapy. The main questions it aims to answer are: Does Nuvastatic significantly reduce cancer-related fatigue compared to placebo? Is Nuvastatic safe and well tolerated in this patient population? Researchers will compare Nuvastatic vs placebo to see if Nuvastatic improves fatigue scores and maintains an acceptable safety profile. Participants will: Receive Nuvastatic or placebo sachets (3 times per day) for 3 cycles of 20 days each (total \~60 treatment days). Continue their standard first-line chemotherapy regimen. Provide blood samples for biomarkers (CEA, CA-125) at Screening and End of Treatment. Complete patient diaries and fatigue assessments as per protocol.
This description comes directly from the study's public registry record.
Aman Shah Abdul Majid, MBChB, DPhil · +605-2490500 · amanharvard2020@outlook.com
Always discuss trial participation with your own doctor first.
| Department of Medical Oncology (In Charge - Oncology Unit) | Srikakulam, Andhra Pradesh, India | Recruiting |
| Hanji Cancer Centre | Belagavi, Karnataka, India | Recruiting |
| K.R. Hospital, Mysore Medical College & Research Institute | Mysuru, Karnataka, India | Recruiting |
| Onco- Life Cancer | Satara, Maharashtra, India | Recruiting |
| Onco-Life Cancer Centre, Pvt. Ltd | Talegaon Dābhāde, Maharashtra, India | Recruiting |
| Avicenna Hospital | Lucknow, Uttar Pradesh, India | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07669519